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Summary 
Insulin-dependent  diabetes meUitus (IDDM) is an autoimmune disease that results in the destruction 
of the pancreatic islet 3  cells.  Glutamic acid decarboxylase (GAD) has been recently indicated 
as a key autoantigen in the induction of IDDM in nonobese diabetic mice. In human diabetes, 
the mechanism by which the 3  cells are destroyed is still unknown.  Here we report the first 
evidence for the presence of GAD-specific cytotoxic T cells in asymptomatic and recent diabetic 
patients.  GAD65 peptides displaying the human histocompatibility leukocyte antigen (HLA)- 
A*0201 binding motif have been synthesized. One of these peptides, GAD114-123, binds to HLA- 
A*0201 molecules in an HLA assembly assay. Peripheral blood mononudear cells from individuals 
with preclinical IDDM, recent-onset IDDM, and from healthy controls were stimulated in vitro 
with the selected peptide in the presence of autologous antigen-presenting  cells. In three cases 
(one preclinical IDDM and two recent-onset IDDM), we detected specific killing of autologous 
antigen-presenting  cells  when incubated with  GAD114-123 peptide or when infected with  a 
recombinant vaccinia virus expressing GAD65. These patients were the only three carrying the 
HLA-A*0201 allele among the subjects studied. Our finding suggests that GAD-specific cytotoxic 
T  lymphocytes may play a critical role in the initial  events of IDDM. 
I 
nsulin-dependent  diabetes mellitus (IDDM) is caused by 
￿9  pathological T cell responses that lead to the destruction 
of 3 cells in the pancreatic islets. Recent studies suggest that 
MHC class II-restricted CD4 + T  cells specific for peptides 
derived from glutamic acid decarboxylase (GAD65) play a 
crucial role in the initial phase of IDDM in nonobese dia- 
betic (NOD) mice (1, 2). GAD-specific CD4 + T  cells have 
also been observed in recent-onset IDDM patients and in rela- 
tives of IDDM patients  at risk to develop diabetes (3).  In 
addition to CD4 +, CD8 + T  cells have also been shown to 
be involved in the pathogenesis of the disease.  Induction of 
diabetes  in  adoptive  transfer  experiments  requires  both 
CD4 + and CD8 + T cells (4, 5). In addition, CD8 + T lym- 
phocytes were the predominant  cells in the inflamed islets 
of an acutely diabetic patient  (6). 
In  this  study we demonstrate  that  MHC class  I  HLA- 
A*0201-restricted CD8 + CTLs specific for a GAD peptide 
(GAD114-123)  are present in the peripheral blood of sub- 
jects with recent-onset IDDM and at high risk to develop 
IDDM.  This peptide is generated by natural  processing of 
human  GAD65.  GAD-specific  CTLs  were  not  found  in 
healthy individuals expressing HLA-A*0201. These findings 
argue for a critical role of GAD-specific CTLs in the initial 
events of IDDM. 
Materials and Methods 
Peptide Synthesis.  Nine peptides conforming to the 3,'0201 motif 
were identified and synthesized by the solid-phase peptide meth- 
odology using a synthesizer (Fmoc/tBu chemistry) (431A; Applied 
Biosystems, Inc., Foster City, CA). Crude peptides were purified 
by reverse-phase HPLC. The identities of the purified peptides were 
confirmed by amino acid analysis and fast atom bombardment mass 
spectrometry. Peptides were dissolved in DMSO at a concentra- 
tion of 2 raM. 
Subjects.  Preclinical IDDM subjects (2 female, 2 male, mean 
age 29.5 yr, range 13-56), defined operationally as asymptomatic, 
were first-degree relatives of patients with IDDM and were found 
to have islet cell antibodies at a level ~>20 Juvenile Diabetes Foun- 
dation U. Recent-onset IDDM subjects (14 female, 8 male, mean 
age 25.4 yr, range 14-44) were insulin dependent, having presented 
with typical clinical features of IDDM in the previous 2 wk. Con- 
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32.5 yr, range 26-45). Peripheral  blood was taken after informed 
consent was obtained. 
HLA Typing.  All of the individuals analyzed were initially HLA- 
typed by standard serological  techniques (7).  To those found to 
be HLA-A2 + (11 out of 26), the A2 subtypes were assigned  ac- 
cording to the hybridization pattern obtained with subtype-specific 
probes after specific amplification of the A2 locus  (8). 
HLA  Assembly Assay.  The T2 cells  were washed  twice in 
serum-free medium.  1  ￿  10  S cells in 40/~1  serum-free medium 
were put into a U-bottom 96-wen plate together with 10 #1 of 
the peptide at a final concentration of 100/~M and 15 #g/ml of 
human ~2-microglobulin (Sigma Chemical Co., St. Louis, MO). 
After overnight incubation at 37~  the cells were washed once 
and stained by indirect immunofluorescence.  The HLA-A2.1-specific 
mAb BB7.2 (50/.d of hybridoma supernatant) was added for 30 
min on ice. The cells were washed and 10/~1 FITC-labeled goat 
anti-mouse Ig (Becton Dickinson and Co., Cockeysville, MD) was 
added. After 30 min on ice,  the cells were washed, and fluores- 
cence was measured on a FACScan  |  flow cytometer (Becton Dick- 
inson and Co.). 
Generation of GAD-specific Cytotoxic T  Cell Lines.  Peripheral 
blood lymphocytes were separated from whole blood and incubated 
at 2  x  106 cells/ml in a 24-well  plate together with autologous 
adherent cells (obtained by a 2-h adherence) that had been pulsed 
overnight with 100/~M of peptides that had bound to HLA-A2 
in the HLA assembly assay. The influenza matrix peptide M58-66 
was included as control. On day 5, 10 U/ml human recombinant 
IL-2 (Hoffmann-La Roche, Inc., Nutley, NJ) was added, and CTL 
assay was done on day 8. 51Cr-labeled PHA-blasts or EBV-B cells 
were preincubated for 1 h with 25 /~M of peptide and without 
peptide, and a 4-h assay was done as described (9).  Assays were 
done at effector to target cell ratios ranging from 100:1 to 1:1. 
Construction of  a Recombinant Vaccinia-expressing GAD.  For the 
production of GAD65 recombinant vaccinia, a full-length human 
GAD65 cDNA was generated from two overlapping cDNA frag- 
ments obtained from A.  Lernmark (University of Washington, 
Seattle,  WA). A 5' GAD fragment (contained in clone 11) com- 
prising the translation initiation codon was amplified in 20 cycles 
using  the primers  (sense)  5'.CTGGATCCAACCATGGCATCT- 
CCGGGCTCTG.3' and (antisense)  5'.GTTGGTCTGCCAATT- 
CCCAATTA.Y. The PCR product was digested with BamHI and 
PstI, and the resulting 260-bp fragment was used to replace the 
corresponding fragment in clone 11. After transfer of a 3' XbaI/Bglll 
fragment from clone 1.9  (containing  the 3' fragment of GAD 
cDNA) into Bluescript SKI  I +  (Stratagene,  Inc., La Jolla, CA), the 
XbaI site in the resulting plasmid was opened, blunt-ended, and 
converted into an EcoRl site by linker ligation. The plasmid was 
then digested with BgllI/KpnI and ligated in a triple ligation to 
a KpnI/NsiI 5' fragment from the modified clone 11 and to a cen- 
tral NsiI/BgllI fragment from clone 1.9. To create a suitable transfer 
vector for the full-length cDNA, the vaccinia virus vector pSC65 
(obtained from Dr. B. Moss, National Institute of Allergy and In- 
fectious Diseases,  National Institutes of Health, Bethesda, MD) 
was modified by insertion of an oligonucleotide containing SpeI, 
NotI, and ScalI sites between the Pacl and KpnI sites in the poly- 
linker.  GAD  cDNA  was  inserted  into  modified  pSC65  as  a 
KpnI/NotI fragment. The construction of recombinant vaccinia 
virus controlling GAD65 expression was performed using standard 
methods. To verify expression of the human GAD65 protein by 
human cells infected with recombinant Vacc/hGAD, immunoblot- 
ring and immunoprecipitation experiments with the mAb GAD6 
were performed. Human EBV-transformed B cells infected with 
Vacc/hGAD 24 h before analysis expressed large amounts of a recom- 
binant 65-kD protein that could be precipitated by GAD6 and also 
reacted with GAD6 in Western blots. No GAD6 immunoreactivity 
was detected in control cells that had been infected with a control 
virus (Vacc/TAP1) that contained the human TAP1 gene. Vacc/TAPl 
had been constructed similarly  to Vacc/hGAD,  using modified 
pSC65 and the vaccinia strain WR (P. M.  Van Endert, unpub- 
lished results). The cloning of the human TAP1 cDNA is described 
elsewhere (10). EBV-B cells at 3  ￿  1@ cells/ml were infected with 
Vacc/hGAD or Vacc/TAP for 2 h at 37~  at a multiplicity of 5 
PFU/cell in medium containing 2.5% FCS. The cells were then 
washed twice and let to stand overnight at 37~  The next day, 
cells were pelleted and labeled with 50 #1 of SlCr. CTL assay was 
performed as described  above. 
IFN-y Production.  IFN-y production was evaluated by a solid- 
phase  sandwich immunoenzymatic assay as described (11). 
Results and Discussion 
GAD65 is highly expressed in the cytoplasm of pancreatic 
B cells (12). GAD-derived peptides, therefore, may be presented 
by MHC class I molecules and recognized by CD8 + T  cells 
on the surface of ~  cells.  To test this possibility, we first de- 
termined the potential of GAD-derived peptides to bind to 
HLA-A*0201,  an MHC class I molecule with well-charac- 
terized peptide binding properties (13-15). HLA*0201 mol- 
ecules bind peptides that are 9 or 10 residues long and con- 
tain 2  major anchor residues:  either leucine, isoleucine,  or 
methionine at position two, and a hydrophobic aliphatic res- 
idue at the COOH terminus. Secondary anchor positions were 
also identified at positions one, three, and seven. In human 
GAD65, nine peptides corresponding to the proposed motif 
were identified. These peptides were synthesized and tested 
for binding by an HLA assembly assay using the T2 cell line 
(16,  17). 
T2 cells showed HLA*0201 expression after incubation with 
peptide GAD114-123 and with the influenza peptide M58-66 
used as a positive control (Fig. 1). We therefore added GAD114- 
123 peptide to cultures containing PBMC from four individ- 
uals with preclinical IDDM, including one expressing A*0201; 
22 diabetic patients, including two expressing A*0201; and 
six  healthy  A*0201 +  donors.  8  d  later  the  cultures  were 
tested for cytolytic activity against peptide-pulsed autologous 
targets, Peptide-specific cytotoxicity was observed in cultures 
containing  cells from  the  three A*0201 §  individuals  with 
preclinical IDDM  and recent-onset IDDM, but not in any 
other culture.  The data shown in Fig.  2  are representative 
of results obtained with GAD114-123-stimulated cultures from 
one subject  with  preclinical  IDDM  and  one patient  with 
recent-onset IDDM. The CTL activity observed from a second 
patient with recent-onset IDDM was lower but clearly de- 
tectable (13%  specific lysis at an effector to target ratio of 
10:1, 9% at 3:1, and 6% at 1:1) (data not shown). The CTL 
activity was GAD114-123-specific, since autologous targets 
incubated with an A*0201-binding control peptide were not 
lysed (Fig. 2, A  and B). As expected, the peptide recognition 
was  A*0201  restricted,  since  killing  was  inhibited  by  an 
A*0201-specific mAb (not shown), and, in ~ panel of EBV-B 
cell lines, only A*0201 + cells were lysed (Fig. 2, C  and D). 
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Figure  1.  Induction of surface HLA-A2 expression in T2 cells. Aliquots of T2 cells (2  x  105) were incubated overnight at 37~  in medium con- 
taining 1% DMSO or in medium containing 0.5 #M B2-microglobulin and (A) 100/~M GADl14-123 peptide (sequence: VMNILLQYVV);  (B) 100 
/xM M58-66 peptide (sequence: GILGFVFTL);  or (C) 100/~M GAD203-212 peptide (sequence: NMFTYEIAPV).  Surface HLA-A2 expression was 
detected by FACS  |  analysis of cells stained with the A2.1-specific mAb BB7.2 (ATCC HB 82). The logarithm of fluorescence intensity is plotted on 
an arbitrary scale from  1 to 80. One representative experiment  out of five is shown. 
All of the individuals analyzed were initially HLA-typed 
by standard serological techniques. To those found to be HLA- 
A2 +  (11  out  of 26),  the  A2  subtypes  were  assigned  ac- 
cording to the hybridization pattern obtained with subtype- 
specific  probes after  specific amplification of the A2 locus. 
To date,  11 subtypes of HLA-A2 have been defined, differing 
from one another in one to six amino acid residues. Most of 
the variations are located in the peptide-binding cleft and scat- 
tered  in the  six peptide  side chain-binding  pockets.  With 
the oligonucleotide probes we used, we were unable to dis- 
tinguish between  the two closely related  subtypes A*0201 
and A*0206.  However, A*0201 only differs from A*0206 by 
the conservative substitution F --~ Y  at position 9. Previous 
analysis  of peptide binding between  some of the HLA-A2 
subtypes has indicated that a broad cross-reactivity exists be- 
tween  HLA-A*0201  and A*0206  (18). 
An important issue is whether the GADl14-123-specific 
CTLs can recognize target cells expressing naturally processed 
native GAD65.  Since A*0201-expressing  islet  cell lines  are 
not available,  we infected autologous EBV-B cell lines with 
a recombinant  vaccinia  virus expressing  the  GAD65  gene 
(Vacc/hGAD). As shown in Fig. 2 (/t and B), the Vacc/hGAD- 
infected targets were lysed. No lysis was observed with control 
targets infected with a recombinant vaccinia virus expressing 
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Figure  2.  In vitro lytic activity of CTL from one sub- 
ject with preclinical IDDM (.4 and C) and one patient 
with newly diagnosed IDDM (B and D). (.4 and B) Cells 
from both subjects showed cytolytic activity toward au- 
tologous PHA-blasts when incubated with GAD114-123 
peptide (O), but not when incubated with medium alone 
(D) or with M58-66 peptide (O). Autologous PHA-blasts 
infected with a recombinant vaccinia virus that express 
human GAD65 were also lysed (A). No cytolysis was ob- 
served when autologous PHA-blasts were infected with 
a recombinant vaccinia virus that expresses the human 
transporter TAP-1 (A). (C and D) Cells from both sub- 
jects showed cytolytic activity toward autologous EBV-B 
cells (O,  C),  autologous  PHA-blasts  (O,  D),  and 
A*0201 §  EBV-B cell  line  BSM  (A)  pulsed  with 
GAD114-123  peptide, but not towards the EBV-B cell lines 
SWEIG (HLA-A29) (e), DKB (HLA-A24) (A, D), or 
FC (HLA-A1,3) (A, C) pulsed with GAD114-123 pep- 
tide. In both cell lines, >80% of the T cells were CD8 § , 
as revealed by FACS  |  analysis. 
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IFN-3, (pg/ml) 
Ag  Pre-IDDM  Early IDDM 
none  ~<6  ~<6 
GAD114-123  520  170 
GAD-VAC  155  60 
GAD203-212  ~<6  ~<6 
* GAD114-123-specific CTLs described  in Fig. 2 were incubated  in the 
presence of irradiated autologous  EBV-B cells that had been pulsed with 
peptide GAD114-123 or peptide GAD203-212 or infected with Vacc/ 
hGAD. 
an irrelevant control gene (Vacc/TAP1).  This indicates that 
GAD114-123  peptide is generated by the processing of the 
GAD protein and represents  a natural dominant epitope. 
Our finding of CD8 + GAD-specific cytolytic T  cells in 
asymptomatic as well as in early diabetic patients suggests 
that CD8 + T  cells are involved in the initial stages  of the 
diabetogenic process. Interestingly, the GAD-specific CTLs 
seem to be activated only in the early development of the 
disease, perhaps as early as CD4 + T  cell responses.  This is 
suggested by the fact that we have not been able to isolate 
CTLs specific for GAD from peripheral blood of the same 
subjects collected 2 and 6 mo after the onset of diabetes (data 
not shown). 
MHC class II-restricted T cells are thought to play a piv- 
otal role in the pathogenesis of IDDM. This view is sup- 
ported by several lines of evidence. First, IDDM only occurs 
in mice and humans expressing certain MHC class II alleles 
(19). Second, the disease can be transferred by a CD4 + T 
cell clone (20).  Third, the incidence of IDDM is increased 
in NOD mice expressing a transgenic TCR cloned from a 
diabetogenic CD4 + T  cell line (21). Fourth, IDDM does 
not occur in NOD mice in which T cell tolerance has been 
induced by intravenous or intrathymic injection of GAD (1, 
2).  None of these findings, however,  exclude a pathogenic 
role of CD8 §  cytotoxic T  cells.  Indeed,  experiments in- 
volving the transfer of T  cell subsets  into neonatal (4)  or 
athymic NOD mice (5),  as well as the depletion of T  cell 
subsets by the in vivo administration of antibodies (for re- 
view see reference  22),  do indicate that both  CD4 + and 
CD8 + T  cells are involved in the development of IDDM. 
Furthermore, these and other reports (23-27)  suggest that 
class I-restricted recognition is as important as class II-re- 
stricted recognition. 
The CTLs described  here kill GAD-expressing cells and 
may thus contribute to the development of IDDM by killing 
cells. In addition to their cytolytic potential, GAD-specific 
CTLs produced IFN-T in response to GAD114-123 peptide- 
pulsed, as well as to Vacc/hGAD-infected,  HLA-A*-0201-ex- 
pressing cells (Table 1). The early production of IFN-3, might 
play a role in promoting the development of type I diabetes. 
Indeed, it has been shown that expression  of the gene en- 
coding IFN-3, under the control of the insulin promoter 
resulted in inflammation in the islets and diabetes in trans- 
genic mice (28). Furthermore, IFN-3~ might have an impor- 
tant immunoregulatory role in vivo by promoting the devel- 
opment of autoreactive  CD4 § T cells able to induce IDDM 
in genetically susceptible  individuals (29).  In this context, 
IFN-y has been shown to be a strong inducer of Thl re- 
sponses while inhibiting the differentiation and effector func- 
tion of the Th2 cells. Evidence suggesting a pathogenetic 
role for Thl cells in IDDM has recently been provided by 
studies  in NOD mice (30-32). 
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